Shares of Allergy Therapeutics plc (LON:AGY – Get Free Report) were up 6.9% during mid-day trading on Thursday . The company traded as high as GBX 5.96 ($0.08) and last traded at GBX 5.88 ($0.07). Approximately 591,028 shares traded hands during trading, a decline of 15% from the average daily volume of 695,330 shares. The stock had previously closed at GBX 5.50 ($0.07).
Allergy Therapeutics Stock Performance
The company has a debt-to-equity ratio of 37.22, a quick ratio of 1.48 and a current ratio of 1.40. The stock has a fifty day moving average of GBX 5.05 and a 200-day moving average of GBX 4.84. The company has a market cap of £262.35 million, a PE ratio of -86.67, a PEG ratio of -30.70 and a beta of 1.40.
About Allergy Therapeutics
Allergy Therapeutics plc, a commercial biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics.
Recommended Stories
- Five stocks we like better than Allergy Therapeutics
- CD Calculator: Certificate of Deposit Calculator
- Fast-Growing Companies That Are Still Undervalued
- What is Forex and How Does it Work?
- Top Cybersecurity Stock Picks for 2025
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Archer or Joby: Which Aviation Company Might Rise Fastest?
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
